Raynaud's Disease Causes, Symptoms, and Treatment

Last updated by Peer reviewed by Dr Laurence Knott
Last updated Meets Patient’s editorial guidelines

Added to Saved items
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Raynaud's Phenomenon article more useful, or one of our other health articles.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonyms: Raynaud's phenomenon

Raynaud's disease was discovered by Maurice Raynaud (a Parisian physician) in the latter half of the nineteenth century. Raynaud's disease is characterised by a paroxysmal vasospastic and subsequent vasodilatory chain of events affecting peripheral arterioles, usually in the hands and feet. It commonly occurs as a response to cold exposure but may also be precipitated by emotional turmoil. The process may occur as a primary entity or secondary to other disease processes.

The pathogenesis of Raynaud's disease is complex but abnormalities of the blood vessel wall, of neural control mechanisms and of intravascular circulating factors are known to interact and contribute[1] .

Raynaud also has a type of gangrene (symmetrical gangrene of the extremities) and a sign (symmetrical, mottled cyanosis of extremities with patches of erythema and excessive sweating) named after him[2] .

The most common trigger of Raynaud's disease is thought to be exposure to cold. Attacks may even occur after minor changes in temperature, such as moving into an air-conditioned building from a hot summer day. Other reported triggers include emotional stress, medications such as beta-blockers, injury due to vibrations or forcible trauma, extended use of digits, smoking and the presence of other arterial diseases, such as vasculitis.

Raynaud's phenomenon is common, occurring less frequently in warmer climates). Most cases (80-90%) of Raynaud's phenomenon are primary.

  • Primary Raynaud's is more common in women and typically develops at a younger age (second or third decade) than secondary Raynaud's.
  • A systematic review reported a pooled prevalence of primary Raynaud's phenomenon of 4.85% and a pooled annual incidence of 0.25%.
  • The main risk factors identified for primary Raynaud's phenomenon were female gender, positive family history, smoking and migraine. Smoking and hand-arm vibration syndrome are more commonly implicated in men.

Secondary Raynaud's is much less common (10-20% of cases) and is the initial manifestation of an associated underlying connective tissue disease, such as scleroderma, dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease, Sjögren's syndrome or rheumatoid arthritis. Over 90% of people with systemic sclerosis have Raynaud's phenomenon.

One UK study among 720 schoolchildren found that 18% of girls and 12% of boys reported a change of colour in their fingers in cold climates at least once a month, or a 'numb or tingly' sensation in the fingers with cold exposure. The prevalence increased with age, especially among the girls[6] .

Raynaud's disease symptoms

  • The patient may initially notice pallor of the distal portion of one or more digits. For reasons as yet unknown, the thumb is usually spared[7] .
  • There is usually a clear demarcation line between affected and normal skin.
  • There then follows a feeling of numbness or pain in the digit(s) accompanied by cyanosis (blueing) of the digit.
  • Finally, there is a hyperaemic phase where the digit becomes red and feels warm.
  • Individual patients may show variation in the sequence of these three phases.

Hands in Raynaud's disease

Raynaud's disease
Niklas D, CC BY-SA 3.0, via Wikimedia Commons

By Niklas D, CC BY-SA 3.0 , via Wikimedia Commons

The patient's age and sex will influence the likelihood of this being primary or secondary Raynaud's disease. Enquire about any associated Raynaud's disease symptoms such as migrainous headache, recent joint or muscle pains, rashes, symptoms of infection, weight loss, etc, to detect possible underlying causes.

It is important to take an occupational history and specifically ask about the use of vibrating tools at work or at home. Take a medication history, including over-the-counter/complementary preparations, and ask if anyone in the family has the same problem. Ask if the patient has ever had frostbite, which is thought to increase the risk of subsequent vasomotor hyperactivity.


In primary Raynaud's disease there will usually be nothing to find, as patients rarely present during the event.

  • To detect evidence of an alternative cause for the symptoms, or an underlying disease associated with secondary Raynaud's disease, look for any abnormality in pulses of the affected hand/foot:
    • Note whether there is atrial fibrillation/other cardiac dysrhythmia or murmur, or any other evidence of a cause for embolic disease.
    • Look at the skin of the face for malar rash indicating systemic lupus erythematosus. Look for sclerodactyly, calcinosis or ulcer formation, and carefully seek evidence of vasculitic changes in the nail beds (magnification will help with this), suggesting progressive systemic sclerosis.
    • Examine any joints that are sore, palpate the abdomen to exclude hepato/splenomegaly and check the lymph fields to detect any evidence of malignancy. Examine any other relevant systems if other underlying causes are possible - eg, chest examination if pulmonary malignancy is suspected.

Associated diseases causing secondary Raynaud's phenomenon

Rheumatology/autoimmune diseases

Arterial and vasospastic disorders

Endocrine/metabolic disorders

Mechanical/environmental causes

Malignant diseases




  • Beta-blockers
  • Ergot derivatives
  • Combined oral contraceptive pill
  • Cytotoxics: bleomycin, vinblastine, cisplatin
  • Interferon (alfa and beta)
  • Methysergide

Many conditions may co-exist as above. The symptom complex is usually fairly distinctive, but other causes of vascular compromise may cause similar symptoms. If in doubt, consider vascular flow imaging/vascular surgical advice. Possible diagnoses that are not classically associated as causative diseases but which may cause symptoms that resemble Raynaud's phenomenon are:

  • In classically presenting primary Raynaud's disease, in a young woman who is well and has no evidence of other causes on examination, you are unlikely to detect anything on investigation:
    • It is probably worth checking FBC, antinuclear antibodies and CRP/ESR/plasma viscosity in this situation as basic screening for unrecognised associated disease.
    • If there is reason to suspect an underlying cause then investigations should be directed to confirming or refuting the association as below:
      • Consider U&E/liver function/thyroid function testing as the basic screening tests in appropriate patients. The presence of specific autoantibodies - eg, antinuclear antibodies - may suggest underlying inflammatory disease. Check plasma glucose for possible diabetes. Urine/serum protein electrophoresis, cold agglutinins and fibrinogen levels may identify hyperviscosity states. CXR (thoracic outlet views) may show a cervical rib.
  • Refer patients with suspected secondary Raynaud's disease for capillaroscopy if available. Other investigations performed in secondary care include infrared thermography, laser Doppler flowmetry, portable radiometry, and digital plethysmography[10] .


  • Younger age (<30, but can be any age); female; genetic component (30% have an affected first-degree relative).
  • No symptoms/signs of underlying disease; no tissue necrosis or gangrene; normal nail fold capillaries.
  • Normal ESR; negative antineutrophil antibodies.


  • Older age (>30, but can be any age); less common (10-20%).
  • Symptoms and signs of underlying disease; tightness of finger skin; more severe pain; digital ischaemia (digital pitting scars, ulceration, or gangrene); abnormal nail fold capillaries.
  • Raised ESR; positive antineutrophil antibodies or anti-extractable nuclear antigen antibodies.


  • Self-help measures
    • Smoking cessation - this is the most important self-help measure.
    • Avoid exposure to cold and take precautionary measures before exposure to cold; use gloves or electrically heated mittens in the winter (available from patient support groups via specialist outfitters - see 'Further reading & references' section, below).
    • Change occupation/DIY habits if vibration is a likely underlying cause.
  • Topical agents
    • Evidence on topical nitrates is limited but studies have shown that[10] :
      • Topical glyceryl trinitrate applied to the dorsum of the finger results in digital vasodilatation with fewer systemic side-effects than with oral nitrates.
      • Nitroglycerin applied to the affected finger reduces the severity of Raynaud's phenomenon but not the duration or frequency of attacks.
  • Systemic agents
    • Calcium-channel blockers: these are most widely used in the treatment of Raynaud's phenomenon. Nifedipine promotes relaxation of vascular smooth muscle cells and leads to vasodilatation[10] .
    • A Cochrane review found low to moderate quality evidence that calcium-channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, and severity of attacks, and also pain and disability associated with primary and secondary Raynaud's phenomenon[12] .
    • Apart from calcium-channel blockers, which are considered to be the drugs of choice, evidence of the effects of alternative pharmacological treatments is limited. A Cochrane review found that evidence is insufficient to support the use of vasodilators and suggests that vasodilator use may even worsen disease[13] .
    • Intravenous prostaglandins: intravenous iloprost has been shown to reduce the frequency and severity of attacks[10] .
  • Surgery[10]
    • Surgical intervention may be considered for severe and disabling symptoms.
    • Surgical interventions include arterial reconstruction, peripheral sympathectomy, embolectomy and ulcer debridement, or a combination of techniques.
    • Cervical sympathectomy is no longer recommended..

Optimal management of the underlying cause can alleviate the symptoms but, unfortunately, many cases do not seem to respond well and persist despite best treatment of the precipitating illness. General/preventative measures are the same as for primary Raynaud's disease as above. Those cases associated with progressive systemic sclerosis are often most troublesome and may lead to severe digital ischaemia and gangrene. See also the separate Systemic Sclerosis (Scleroderma) article.

Most patients can be managed in primary care[14] . However, referral should be considered in the following circumstances[3] :

    • Admit immediately if the person has severe ischaemia of one or more digits.
    • Refer:
      • Suspected secondary Raynaud's phenomenon.
      • Children aged 12 years or younger with Raynaud's phenomenon.
      • Symptoms worsening, severe or unresponsive to standard treatment.
    • Most causes will be due to connective tissue disorders and referral to a rheumatologist would be appropriate. If an occupational cause is suspected, refer to an occupational medicine specialist or vascular clinician with expertise in this area (depending on local protocol)..

Primary Raynaud's is typically benign and does not progress or lead to tissue damage. Studies have found rates of remission (no attacks for two cold seasons, or 12 months without symptoms) between 3% and 33% after 7-14 years. The frequency and severity of symptoms fluctuate with changes in daily temperature and may lessen with increasing age.

An underlying disorder develops in 13% of cases of the primary form. Primary Raynaud's disease may go into remission. Most patients have a stable course and over half improve over time[15] . Secondary cases are more prone to be problematic - ulceration, scarring, or gangrene occur in 17% of people with Raynaud's disease secondary to systemic sclerosis[16] .

Severe cases may lead to digital infarction and gangrene with loss of the tissue of the finger pulp or distal phalanx. The skin may become chronically ischaemic and ulcerate. The digit(s) may lose viability and require amputation in the very worst cases.

  • Avoid smoking[14] .
  • Avoid beta-blocker treatment.
  • Wear gloves or have them to hand at all times.
  • Use specialist heated gloves if necessary.
  • Anticipate exposure to cold and take appropriate ameliorative steps.
  • Advise considering moving to warmer climes (particularly during the coldest months) if the condition is troublesome enough and the patient has the resources to do so.
  • Avoid use of vibrating hand tools.

Further reading and references

  1. Herrick AL; The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10.

  2. A. G. Maurice Raynaud; Whonamedit.com

  3. Raynaud's phenomenon; NICE CKS, February 2020 (UK access only)

  4. Garner R, Kumari R, Lanyon P, et al; Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015 Mar 165(3):e006389. doi: 10.1136/bmjopen-2014-006389.

  5. Maverakis E, Patel F, Kronenberg DG, et al; International consensus criteria for the diagnosis of Raynaud's phenomenon. J Autoimmun. 2014 Feb-Mar48-49:60-5. doi: 10.1016/j.jaut.2014.01.020. Epub 2014 Feb 1.

  6. Goldman RD; Raynaud phenomenon in children. Can Fam Physician. 2019 Apr65(4):264-265.

  7. Chikura B, Moore TL, Manning JB, et al; Sparing of the thumb in Raynaud's phenomenon. Rheumatology (Oxford). 2008 Feb47(2):219-21.

  8. Herrick AL; Evidence-based management of Raynaud's phenomenon. Ther Adv Musculoskelet Dis. 2017 Dec9(12):317-329. doi: 10.1177/1759720X17740074. Epub 2017 Nov 20.

  9. Khouri C, Blaise S, Carpentier P, et al; Drug-induced Raynaud's phenomenon: beyond beta-blockers. Br J Clin Pharmacol. 2016 Mar 7. doi: 10.1111/bcp.12912.

  10. Goundry B, Bell L, Langtree M, et al; Diagnosis and management of Raynaud's phenomenon. BMJ. 2012 Feb 7344:e289. doi: 10.1136/bmj.e289.

  11. Landry GJ; Current medical and surgical management of Raynaud's syndrome. J Vasc Surg. 2013 Jun57(6):1710-6. doi: 10.1016/j.jvs.2013.03.012. Epub 2013 Apr 23.

  12. Rirash F, Tingey PC, Harding SE, et al; Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database Syst Rev. 2017 Dec 1312:CD000467. doi: 10.1002/14651858.CD000467.pub2.

  13. Su KY, Sharma M, Kim HJ, et al; Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021 May 175:CD006687. doi: 10.1002/14651858.CD006687.pub4.

  14. Smith J; Focused assessment with sonography in trauma (FAST): should its role be reconsidered? Postgrad Med J. 2010 May86(1015):285-91. doi: 10.1136/pgmj.2008.076711. Epub 2010 Apr 3.

  15. Jackson CM; The patient with cold hands: understanding Raynaud's disease. JAAPA. 2006 Nov19(11):34-8.

  16. Herrick A; Raynaud's Phenomenon. Curr Treat Options Cardiovasc Med. 2008 Apr10(2):146-55.